Canada Pension Plan Investment Board bought a new stake in DaVita Inc. (NYSE:DVA – Free Report) in the 2nd quarter, Holdings Channel.com reports. The firm bought 119,024 shares of the company’s stock, valued at approximately $26,480,000.
A number of other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of DaVita in the 2nd quarter valued at $547,520,000. Invesco Ltd. raised its stake in DaVita by 2.0% during the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock valued at $223,122,000 after acquiring an additional 32,358 shares during the last quarter. Morgan Stanley lifted its position in DaVita by 5.1% during the 4th quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock worth $167,807,000 after acquiring an additional 71,156 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in shares of DaVita by 114.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after purchasing an additional 636,191 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of DaVita by 5.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock valued at $176,037,000 after purchasing an additional 56,336 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on DVA shares. TD Cowen upgraded shares of DaVita from a “hold” rating to a “buy” rating and lifted their price objective for the company from $201.00 to $220.00 in a research report on Friday, August 7th. Barclays upped their price objective on DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 5th. Raymond James Financial set a $220.00 target price on shares of DaVita in a research report on Friday, August 7th. Finally, Oppenheimer set a $220.00 price objective on DaVita in a report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $221.75.
Insider Buying and Selling
In related news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.90% of the company’s stock.
DaVita Price Performance
Shares of NYSE DVA opened at $180.72 on Friday. The company has a 50-day simple moving average of $211.96 and a 200-day simple moving average of $183.05. The company has a market cap of $11.53 billion, a PE ratio of 14.79, a price-to-earnings-growth ratio of 0.46 and a beta of 0.88. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $247.49.
DaVita (NYSE:DVA – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. During the same quarter in the prior year, the firm posted $2.95 earnings per share. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, analysts anticipate that DaVita Inc. will post 14.57 EPS for the current year.
DaVita Profile
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
Read More
- Five stocks we like better than DaVita
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
